Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness

NCT01802944 | Unknown Phase 2

• 1 other identifier: GW110054
• Study Type: interventional
• Target: 114
• Locations: 1 country
• Sites: 2

Brief Summary

Following their deployment to the 1991 Gulf War, many veterans (GWV) reported a constellation of unexplained health symptoms; common among them were attention and memory difficulties, fatigue, joint pain, headaches, gastrointestinal complaints, and mood and sleep problems. Despite the passage of time, the symptom complex persists for many veterans. Indeed, it is estimated that at least 25 percent of GWV (nearly 170,000 veterans) have a persistent form of chronic multisymptom illness (CMI). GW deployed veterans are also developing significantly more chronic diseases such as diabetes, hypertension, arthritis, and coronary heart disease than their non-deployed veteran peers putting these individuals at risk for accelerated aging-related diseases of the peripheral and central nervous system (CNS). Recent studies have shown a slowing of response speed that affects mental flexibility across multiple cognitive domains (memory, attention, visuospatial functions) especially on tests that were timed and computerized and where small differences in cognitive reaction times could be measured. Recent studies also have suggested that the response inhibition deficits shown in GWV may reflect executive system dysfunction as reflected by slower motor responses across multiple cognitive domains. To date, there are no treatments that have been shown to improve the health or cognitive difficulties of GW veterans; thus there is an urgent need to establish effective, safe, and tolerable treatments for GW CMI. Previous studies in other cognitive disorders have found that intranasal insulin improves memory, attention, and mood, reduces neuroinflammation, and modulates cortisol levels; it has also been identified as a treatment that has the capacity to alter many of the leading problems of GW CMI. During this study there are 2 treatment groups and a placebo group that will last for 8 weeks. The treatment groups will self-administer their designated dosage of insulin through a nasal pump twice a day, while the placebo group will administer saline through a nasal pump twice a day. These doses have been shown to be effective and safe. The primary outcome measure will assess improvements in verbal delayed memory using a specific list learning task and on a measure of selective attention. The study will assess improvements in overall physical health and mood by asking the participants to complete self report questionnaires. Neuroendocrine measures will also be obtained in order to evaluate changes in glucose, insulin, and cortisol levels and examine their impact on GW CMI. Intranasal insulin has shown great promise in improving memory, attention, and mood in both older adults with cognitive impairment as well as normal subjects. Thus, this proposal could prove intranasal insulin to be an effective, safe, and affordable therapy for these ailing veterans.

Conditions

Chronic Multisymptom Illness in Gulf War Veterans

Outcome Measures

Primary Outcomes (2)

• Memory Functioning

  To assess the efficacy of two different doses (10 IU BID and 20 IU BID) of daily intranasal insulin for eight weeks on memory functioning in Gulf War Veterans with Chronic Multisymptom Illness. The primary clinical outcome measure will be a change in the performance on the delayed verbal memory score on a list learning task (California Verbal Learning Test (CVLT). To determine the sustainability of change in cognitive status, the response from treatment endpoint (end of 8-week treatment period) to one month follow-up (post end of 8-week treatment period) will also be assessed for the primary outcome measure.

  Eight weeks

• Attention Functioning

  To assess the efficacy of two different doses (10 IU BID and 20 IU BID) of daily intranasal insulin for eight weeks on attention functioning in Gulf War Veterans with Chronic Multisymptom Illness. The primary clinical outcome measure will be a change in performance on a selective attention task (Stroop Color-Word Interference Task) from treatment baseline to endpoint. To determine the sustainability of change in cognitive status, the response from treatment endpoint (end of 8-week treatment period) to one month follow-up (post end of 8-week treatment period) will also be assessed for the outcome measure.

  Eight Weeks

Secondary Outcomes (2)

• Physical Health

  Eight weeks

• Mood

  Eight Weeks

Study Arms (3)

10 IU BID

EXPERIMENTAL

10 IU BID Intranasal Insulin

Drug: Intranasal Insulin

20 IU BID

EXPERIMENTAL

20 IU BID Intranasal Insulin

Drug: Intranasal Insulin

PLACEBOS

EXPERIMENTAL

Saline nasal solution used as placebo

Drug: Placebos

Interventions

Intranasal Insulin DRUG

10 IU BID; 20 IU BID

Placebos DRUG

PLACEBOS

Eligibility Criteria

• Age: 40 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is a veteran of the 1991 Gulf War.
• Veteran meets criteria for chronic multisymptom illness based Kansas Gulf War Study (Steele, 2000) criteria and must meet criteria in the cognitive symptom domain.

You may not qualify if:

• Veteran lacks the capacity to provide consent.
• Veteran has diabetes, a major medical or neurological disorder or moderate-severe traumatic brain injury.
• Veteran has a history of hypoglycemia.
• Veteran is taking oral or nasal corticosteroids, insulin or oral hypoglycemic agents.
• Veteran has an irregular nasal cavity (i.e. nasal polyps etc.) or is using nasal sprays on a regular basis.
• Veteran has a lifetime diagnosis of schizophrenia, schizoaffective disorder or type I bipolar disorder.
• Veteran is at high risk from a mental perspective as evidence by having been psychiatrically hospitalized or attempted suicide within the previous 2 years or has current active suicidal ideation.
• Veteran is pregnant or breastfeeding or plans to become pregnant within the year.

Sponsors & Collaborators

• Bronx Veterans Medical Research Foundation, Inc: lead
• VA Boston Healthcare System: collaborator
• Boston University: collaborator

Study Sites (2)

VA Boston Healthcare System

Boston, Massachusetts, 02130, United States

RECRUITING

James J. Peters VA Medical Center

The Bronx, New York, 10468, United States

RECRUITING

Study Officials

• Julia Golier, MD

  Chief of Psychiatry Bronx VA Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Allison J Markiewicz, MSW

CONTACT

(718) 584-9000; Allison.Markiewicz@va.gov

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2013
• First Posted: March 4, 2013
• Study Start: April 1, 2014
• Primary Completion: December 1, 2017
• Study Completion: December 1, 2017
• Last Updated: October 6, 2017

Record last verified: 2017-10

Locations

US (2)